Lantus? Or Lente?

Berkowitz, Kathy J.

doi:10.1097/00000446-200208000-00039

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Despite this, studies have continued to show deficiencies in health care professionals' knowledge of insulin use. 6,8,10 This study aimed to quantify the extent of this problem among health care workers and attempted to show the differences in understanding of and knowledge about insulin use among physicians, nurses, and pharmacists.…”

Section: Discussionmentioning

confidence: 99%

“…4 Insulin therapy has grown more complex with the advent of insulin analogs and new insulin regimens, and the presence of knowledge gaps among health care professionals (HCPs) has been one of the important factors resulting in errors in insulin use. 5 This is compounded by similarsounding trade or generic insulin names (e.g., "lente" [an intermediateacting human insulin formulation] and "Lantus" [the trade name for the long-acting insulin analog glargine]) 6 and by systems in which different HCPs are responsible for prescribing and administering insulin. 7 Physicians, nurses, and pharmacists all play important roles in inpatient insulin use.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Insulin-Related Knowledge Among Health Care Professionals at a Tertiary Hospital

Lee¹,

Liu²,

Quek³

et al. 2013

Diabetes Spectrum

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Insulin-Related Knowledge Among Health Care Professionals at a Tertiary Hospital

Lee¹,

Liu²,

Quek³

et al. 2013

Diabetes Spectrum

View full text Add to dashboard Cite

Diabetes mellitus treatment—Related medical knowledge among health care providers

Shahla

Vasudev

Chitturi

et al. 2017

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

Insulin Glargine

Dunn¹,

Plosker²,

Keating³

et al. 2003

Drugs

View full text Add to dashboard Cite

Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in subcutaneous tissue from which small amounts of insulin glargine are gradually released. The plasma concentration versus time profile of insulin glargine is therefore relatively constant in relation to conventional human insulins, with no pronounced peak over 24 hours. This allows once-daily administration as basal therapy. Early randomised trials with insulin glargine generally showed greater reductions in fasting blood or plasma glucose levels and a reduced frequency of nocturnal hypoglycaemia relative to neutral protamine Hagedorn (NPH) insulin in patients with type 1 diabetes mellitus. In addition to this basal therapy, patients continued to use the regular mealtime insulin regimen to which they were accustomed. More recent data with insulin glargine have included evidence of improved glycaemic control, with improvements in satisfaction with treatment over NPH insulin. Furthermore, the time of day at which insulin glargine is injected has no clinically relevant effect on glycaemic control in these patients. There are also data from small, nonblind studies to suggest comparable glycaemic control with insulin glargine and continuous subcutaneous insulin infusion. Results from comparative studies and meta-analyses in individuals with type 2 diabetes show lower incidences of nocturnal hypoglycaemia with insulin glargine than with NPH insulin, with two studies showing a significantly greater improvement in glycosylated haemoglobin levels with insulin glargine than with NPH. Insulin glargine is well tolerated, and is not associated with greater immunogenicity or increases in bodyweight than NPH insulin. Long-term data show maintenance of glycaemic control with insulin glargine for up to 39 months in adults and children with type 1 and adults with type 2 diabetes. In conclusion, insulin glargine is an effective and well tolerated basal insulin therapy when given as a single daily subcutaneous injection to patients with diabetes, with benefits in terms of glycaemic control and reduced frequency of hypoglycaemia over regimens based on conventional basal insulins. Accumulating data and official recommendations show the suitability of insulin glargine for first-line use in selected patients with type 2 diabetes who require insulin treatment, as well as in patients with type 1 disease, and confirm its use in children and adolescents.

show abstract

Lantus? Or Lente?

Cited by 4 publications

References 0 publications

Insulin-Related Knowledge Among Health Care Professionals at a Tertiary Hospital

Insulin-Related Knowledge Among Health Care Professionals at a Tertiary Hospital

Diabetes mellitus treatment—Related medical knowledge among health care providers

Insulin Glargine

Contact Info

Product

Resources

About